News
Stephenson Harwood advises Hong Kong AI business on reverse merger and NASDAQ listing
Stephenson Harwood's Hong Kong corporate team has advised YOOV Group on its proposed reverse merger and listing on NASDAQ.
Stephenson Harwood advises on healthcare data acquisition
Stephenson Harwood LLP has acted for FPE Capital LLP on the acquisition by its portfolio company, Egress, of healthcare data migration specialist Stalis.
Stephenson Harwood advises Lansen Pharmaceutical on privatisation
Stephenson Harwood LLP acted as the Hong Kong legal adviser to Lansen Pharmaceutical Holdings Limited (Lansen Pharmaceutical) on its privatisation by Cathay International Pharma Manufacture And…
Stephenson Harwood advises on $25 million funding in ViaNautis Bio
Stephenson Harwood LLP has advised UCB Ventures, BGF and 4Bio Capital, who led the over-subscribed Series A funding round of $25million in ViaNautis Bio.
Stephenson Harwood advises BenevolentAI on strategic collaboration with Merck
Law firm Stephenson Harwood LLP has advised BenevolentAI on its recent strategic collaboration with Merck.
Stephenson Harwood advises Novacyt on Yourgene Health takeover
Law firm Stephenson Harwood LLP has advised long-standing diagnostics client Novacyt S.A. in relation to its recommended takeover of Yourgene Health plc, an international integrated technologies…
Stephenson Harwood advises Flarin on fundraise
Law firm Stephenson Harwood LLP has advised Flarin, the joint pain relief brand, on its fundraise through existing investor IW Capital and through ITV's Media for Equity investment fund. ITV has…
Stephenson Harwood advises Bicycle Therapeutics on radiotherapy deal with Bayer
Law firm Stephenson Harwood LLP has advised Bicycle Therapeutics plc on its recent strategic collaboration agreement with Bayer to discover and develop Bicycle radioconjugates for multiple…
Stephenson Harwood advises Bicycle Therapeutics on radiopharmaceuticals deal with Novartis
Law firm Stephenson Harwood LLP has advised Bicycle Therapeutics on its recent strategic collaboration agreement with Novartis to discover and develop multiple targeted radioligand therapies in…
Stephenson Harwood advises Oxford Biomedica on new AstraZeneca agreement
Law firm Stephenson Harwood LLP has advised Oxford Biomedica, the gene and cell therapy company, on its new three year Master Services & Development Agreement with AstraZeneca UK Ltd (…
Kristian Shearsby joins Stephenson Harwood as partner
Law firm Stephenson Harwood LLP has strengthened its corporate finance practice, and life sciences and technology sector capabilities, with the arrival of Kristian Shearsby as partner in its…
Stephenson Harwood advises Apposite Capital on Emblation investment
Law firm Stephenson Harwood LLP has advised healthcare investor Apposite Capital on its investment in medical device company, Emblation.
Stephenson Harwood advises e-therapeutics plc on £22.5 million fundraise
Law firm Stephenson Harwood LLP has advised e-therapeutics plc on a fundraise of £22.5 million.
Stephenson Harwood advises GE Healthcare on transformative Zionexa acquisition
Law firm Stephenson Harwood LLP has advised GE Healthcare on the acquisition of Zionexa. GE Healthcare is a medical technology, pharmaceutical diagnostics, and digital solutions company; Zionexa…
Partner Alexandra Pygall joins Babraham Institute Board
Stephenson Harwood partner Alexandra Pygall has been appointed to The Babraham Institute’s Board of Trustees.